But, the latest prospective study, the NEOALTTO trial, fifty newly diagnosed human epidermal growth factor receptor 2-positive BC women received or did not receive anthracycline followed by taxus and trastuzumab for 15 months of follow-up, found NT-pro-BNP measured at the completion of anthracyclines are useful in the prediction of subsequent TIC (Ben Kridis et al., 2020). Here, ERBB2 is linked to breast cancer.